COMPOUND RECORD / XEMYS

XemysКсемис

Immune FunctionRecovery

Source linked

01 / OVERVIEW

About Xemys

Names in this research collection

Liposomal myelin basic protein peptides · FASEMS

A formulation of myelin basic protein peptides in mannosylated liposomes, developed for antigen-directed multiple sclerosis research. The published human program is an uncontrolled Phase I study.

Identity / background source ↗

Research background

Russian-developed liposomal myelin basic protein peptide formulation investigated in an open-label Phase I multiple sclerosis study. Clinical efficacy and restored immune tolerance remain unproven.

Autoimmune research: disease-specific findings, immune effects and open questions ↗

What the studies found

Study involving people · 2016

Who or what was studied20 MS patients enrolled at four Russian centers; open-label Phase I

Reported finding

EDSS and MRI measures were statistically unchanged at study exit. Active gadolinium-enhancing lesions increased transiently at weeks 7 and 10.

EDSS and MRI at study exit: No statistically significant change versus baseline
Active gadolinium-enhancing lesions: Transient increase at weeks 7 and 10

All reported results & study design →

Methods, dose & source notes

Study of this preparation · Publication record; consult source access and review depth

Uncontrolled safety and proof-of-concept study; not evidence of reduced relapses or disability progression. Early MRI activity must be considered alongside the authors’ tolerability findings.

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study ↗

Study involving people · 2016

Who or what was studiedBiomarker analysis from the same Phase I Xemys research program

Reported finding

The paper reports changes in circulating cytokines and chemokines after Xemys exposure.

Methods, dose & source notes

Study of this preparation · Indexed abstract; full methods not assessed

Same clinical program as the Phase I report; not an independent efficacy trial. Biomarker changes do not demonstrate restored immune tolerance or clinical disease modification.

Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients ↗

These highlights cover selected studies. Open a source for its methods, reported doses and full context.

Compound class: Antigen-directed peptide formulation
Research collection: Neuropeptide research · editorial grouping
Research institutions: No institutional affiliation recorded
Source review: Review dates and the material assessed are listed with each publication below.

02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research 20-patient open-label Phase I program
Study methods Safety, clinical measures, MRI and biomarkers
Independent replication Related publications share a clinical program
Source access Original open-access publications
Safety evidence Small early-phase study; transient increased MRI activity reported

Open a topic for the evidence assessment.

More findings, background and history

EVIDENCE REVIEW / 6 OCTOBER 2026

Outstanding review questions

Two publications share one Phase I program. Neutral exit disability/MRI measures and transient increased lesion activity remain visible. Establish later trial identifiers and controlled outcomes before claiming tolerance restoration.

Human reports are linked; their presence does not establish effectiveness. Publication records can share participants. Source counts are not trial counts.

Browse original study records ↗

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2016 · CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation StudyEDSS and MRI at study exit: No statistically significant change versus baseline

2016Human study · design details unresolvedFull text available

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study

A. Belogurov Jr., K. Zakharov, Y. Lomakin, K. Surkov, S. Avtushenko, P. Kruglyakov, I. Smirnov, G. Makshakov, C. Lockshin, G. Gregoriadis, D. Genkin, A. Gabibov, E. Evdoshenko · Neurotherapeutics. 2016;13:895–904

EDSS and MRI measures were statistically unchanged at study exit. Active gadolinium-enhancing lesions increased transiently at weeks 7 and 10.

Findings, study figures and available tables

Reported findings and study design

Uncontrolled Phase I study; 20 MS patients enrolled at four Russian centers.

Reported findings and study figures · Source passages checked 5 November 2026; see study record for access and limitations.
Measure	Result	Comparison, timing and statistics
EDSS and MRI at study exit	No statistically significant change versus baseline
Active gadolinium-enhancing lesions	Transient increase at weeks 7 and 10

Small open-label study cannot establish clinical efficacy, restored tolerance or long-term safety. Early MRI activity remains relevant despite unchanged exit measures.

Source for the extracted data ↗ · Checked 2026-11-05

Population / setting: 20 MS patients enrolled at four Russian centers; open-label Phase I
What was checked: Primary publication checked for Phase I design and clinical/MRI outcomes.

Limitations & review scope

Uncontrolled safety and proof-of-concept study; not evidence of reduced relapses or disability progression.
Early MRI activity must be considered alongside the authors’ tolerability findings.

Source checked 2026-11-05. See the review scope above for the material assessed.

Read the source ↗

2016 · Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients

2016Human study · design details unresolvedEnglish abstract

Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients

Y. Lomakin, A. Belogurov, I. Glagoleva, A. Stepanov, K. Zakharov, J. Okunola, I. Smirnov, D. Genkin, A. Gabibov · Mediators of Inflammation. 2016:2847232

The paper reports changes in circulating cytokines and chemokines after Xemys exposure.

Population / setting: Biomarker analysis from the same Phase I Xemys research program
What was checked: Original publisher summary checked; linked full text available.

Limitations & review scope

Same clinical program as the Phase I report; not an independent efficacy trial.
Biomarker changes do not demonstrate restored immune tolerance or clinical disease modification.

Source checked 2026-11-05. See the review scope above for the material assessed.

Read the source ↗

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗